(UroToday.com) At the 2021 European Association of Urology (EAU) annual meeting, Dr. Jonathan Olivier presents the outcomes of an active surveillance cohort stratified by MRI visible and non-visible lesions. This is part of the work from the GAP3 consortium.
(UroToday.com). At the 2021 European Association of Urology annual meeting, Dr. Jacob Fredsoe presents the ProCaRis trial, which is a risk-adapted screening trial for prostate cancer utilizing single nucleotide polymorphisms (SNPs).
(UroToday.com) In this talk by Dr. Francesco Giganti, he reviews characteristics of MRI lesions that favor active surveillance and helps to monitor MRI lesions in patients on active surveillance.
(UroToday.com) Mr. Cosimo Pieri from Italy kicked off the session on active surveillance for intermediate risk prostate cancer with a patient testimonial. As mentioned made the session chairs, he has been a strong proponent of active surveillance in Italy, Europe, and even internationally.
(UroToday.com) Dr. Antti Rannikko from Finland reviewed the potential for PSA kinetics and other biomarkers as potential replacements for per protocol prostate biopsies for men on active surveillance.
– Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial – – First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously Received One or More Prior Therapies, Based on Cohort 2 of Pivotal EV-201 Trial – San Francisco, CA (UroToday.com) — Seagen Inc. and Astellas Pharma Inc. announced […]
(UroToday.com) Dr. Geert Van Leenders of the Netherlands provides the Pathology perspective on quantifying Gleason pattern 4 for active surveillance (AS). First, he highlights the fact that Gleason pattern for disease is a heterogeneous subset. Historically Gleason pattern 4 was a single entity – but recent research has demonstrated that Gleason pattern has multiple histologic subsets. […]
(UroToday.com) In the final presentation of the session, Dr. Robert Nam from Toronto presents the Canadian study entitled MVP (MRI vs. PSA) Trial, which compares MRI directly against PSA as an initial screening strategy in screening naïve men.
(UroToday.com) Dr. Tobias Nordstrom presented on the Stockholm3 MRI trial, which is a risk-adapted screening protocol incorporating genomics and MRI. The aim of this study was to compare traditional screening with web-based risk prediction combined with MRI-targeted biopsies for prostate cancer screening. This was a population-based screening-by-invitation noninferiority trial. The trial flow diagram is listed […]
San Francisco, CA (UroToday.com) — Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could […]
